Please login to the form below

Not currently logged in
Email:
Password:

Turing names Eliseo Salinas as head of R&D

He joins from Relmada Therapeutics where he was president

edit-Turing-Eliseo-SalinasNew York-based Turing Pharmaceuticals has appointed Eliseo Salinas as president of research and development.

Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia, epilepsy, stroke, Parkinson's, attention deficit disorder and Alzheimer's disease.

Commenting on his new role, Salinas said: “I am excited to be joining Turing. It is a special opportunity to be part of a dynamic young company with an important portfolio of assets in development, a strong management team and a great vision. 

“I look forward to helping to accelerate Turing's success and contribution to healthcare.”

He joins from Relmada Therapeutics, where he served as president and chief scientific officer in addition to holding the role of head of R&D.

Prior to that, Salinas held multiple senior medical and science positions at biopharma companies including Elan Pharmaceuticals, Adolor and Shire, where he served as chief scientific officer.

Martin Shkreli, founder and chairman of Turing, added: “We are pleased to welcome Eliseo Salinas to our leadership team.

“Eliseo combines proven capabilities to bring important new treatments to patients and their physicians, with a deep understanding of the patient and physician communities. His appointment is another major step as we build Turing's capabilities for the long term, advance our existing pipeline and work to create and acquire new assets.”

3rd June 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...
The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...

Infographics